TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Base Study:~  * Patient has Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease and is treated with a statin, with well controlled LDL-C~* Extension Study:~  * Patient has completed the base study including the reversibility period (i.e. 12 or to up to 24 weeks).~ * Patient is on statin therapy ± lipid-modifying therapy since the end of the base study and planning to continue taking a statin throughout the study~Exclusion Criteria:~* History of heart failure, arrhythmias, heart attack, unstable angina, or stroke within 3 months prior to screening, uncontrolled blood pressure, uncontrolled high cholesterol or liver disease.~* History of mental instability, drug/alcohol abuse within the past 5 years~* Pregnant or breast-feeding~* History of cancer within the last 5 years~* HIV positive~* Donated blood products within 8 weeks~* Currently participating or have participated in a study with an investigational compound within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Anacetrapib (Type: EXPERIMENTAL): Participants randomly assigned to anacetrapib in base study will continue same treatment if enrolled in study extension.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomly assigned to placebo in base study will continue same treatment if enrolled in study extension.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have any one of these three disease categories:~   * Idiopathic Pulmonary Arterial Hypertension~     * Mean pulmonary arterial pressure (PAPm) \> 25 millimeters of mercury (mmHg) at rest, pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, and PVRI\> 3 u•m\^2 or diagnosed clinically with no previous catheterization~  * Congenital heart disease (CHD) with pulmonary hypertension repaired and unrepaired~     * PAPm \> 25 mmHg at rest and PVRI\> 3 u•m\^2 or diagnosed clinically with no previous catheterization~  * Cardiomyopathy~     * PAPm \> 25 mmHg at rest and Pulmonary vascular resistance index (PVRI)\> 3 u•m\^2 or diagnosed clinically with no previous catheterization~2. Scheduled to undergo right heart catheterization to assess pulmonary vasoreactivity by acute pulmonary vasodilation testing.~3. Male or female, ages 4 weeks to 18 years, inclusive~4. Signed informed consent/assent~Exclusion Criteria:~1. Focal pulmonary infiltrates on chest radiograph.~2. Diagnosed with severe obstructive or restrictive pulmonary disease that is significantly contributing to the patient's pulmonary hypertension.~3. Received treatment with nitric oxide for inhalation within 30 days prior to study initiation, are on other investigational medications, nitroglycerin, sodium nitroprusside, sildenafil, other Phosphodiesterase type 5 (PDE-5) inhibitors, or prostacyclin~4. Pregnant \[urine human chorionic gonadotropin positive (HCG +)\]~5. Baseline Pulmonary capillary wedge pressure (PCWP) \> 20 mmHg

- Gender: ALL
- Minimum Age: 4 Weeks
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Nitric Oxide First, Oxygen Last (Type: EXPERIMENTAL): 10 minute dose of Nitric Oxide (NO) at 80 ppm, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of 100% Oxygen on Day 1.
- Oxygen First, Nitric Oxide Last (Type: EXPERIMENTAL): 10 minute dose of 100% Oxygen, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of NO at 80 ppm on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes and inadequate glycemic control, defined as A1C ≥ 7.0 and ≤ 10.0% at the enrollment visit~* Subjects should have been receiving either metformin therapy OR metformin therapy AND one insulin secretagogue for at least 12 weeks prior to enrollment~* C-peptide ≥ 1.0 ng/ml (0.34 nmol/l)~* BMI ≤ 45.0 kg/m2~Exclusion Criteria:~* Urine albumin to creatinine ratio (UACR) \> 1,800 mg/g (203.4 mg/mmol/Cr)~* Aspartate Aminotransferase (AST) \> 3X Upper limit of normal (ULN)~* Alanine aminotransferase (ALT) \> 3X ULN~* Serum Total Bilirubin \> 2 mg/dL (34.2 μmol/l)~* Serum Creatinine (Scr) ≥ 1.50 mg/dL (133 μmol/l) for men; SCr ≥ 1.40 mg/dL (124 μmol/l) for women~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glucose Oxidase as Treatment Against Common Cold

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of a common cold within the last 24 hours~Exclusion Criteria:~* Use of a nasal steroid due to allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saline+glucose (Type: PLACEBO_COMPARATOR): A nasal spray with isotone saline + 5% glucose in a bag-on-valve nasal spray device. The spray will be administered with one puff in each nostril 5 times day one and thereafter trice daily for a total treatment time of one week
- Glucose oxidase + glucose (Type: ACTIVE_COMPARATOR): A nasal spray (bag-on-valve device) with 200U/ml glucose oxidase + 5% glucose in isotone saline. One puff in each nostril 5 times daily day one and 3 times daily thereafter. A total treatment time of one week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Affect Dimensions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking~* Low positive affect indexed by less than or equal to 24 on the positive affect subscale of the PANAS (i.e., PANAS-P); and scores of greater than or equal to 11 for depression, greater to or equal to 6 for anxiety, or greater to or equal to 10 for stress on the Depression, Anxiety, and Stress Scale; and scores of greater than or equal to 5 on any Sheehan Disability Scale subscale.~* Willingness to refrain from starting other psychosocial or pharmacological treatments until study completion.~Exclusion Criteria:~* Patient report of serious medical conditions - such as history of serious, uncontrolled medical illness, or instability (including significant cardio-pulmonary disease, organic brain syndrome, seizure disorder, cerebrovascular disease, thyroid dysfunction, and diabetes)~* Active suicidal ideation~* Lifetime history of bipolar disorder, psychosis, mental retardation, or organic brain damage~* Substance abuse in the last 6 months or dependence within last 12 months.~* 11 or more cigarettes per week or nicotine equivalent.~* History of marijuana, cocaine or stimulant use 5-7 times/week or more before age 15 (e.g., amphetamine, cocaine, methamphetamine)~* Pregnancy~* Bupropion, dopaminergic or neuroleptic medication use in the past 6 months~* Heterocyclics and SSRIs are permitted if stabilized (3 months) and PRN benzodiazepines and beta-blockers are permitted but discouraged on laboratory assessment visits~* Refusal of video/audio-taping

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Positive Affect Treatment (Type: EXPERIMENTAL): 15 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning.
- Negative Affect Treatment (Type: ACTIVE_COMPARATOR): 15 sessions of psychotherapy designed to decrease threat avoidance, threat appraisal and arousal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males age 18-26~Exclusion Criteria:~* Hospitalization within the past year~* Previous HPV vaccination~  \>/=5 sexual partners (i.e., insertive intercourse) No other drug studies within 30 days of proposed HPV vaccination~* History of genital warts~* Immunosuppression~* Other vaccines within 8 days of proposed HPV vaccination~* Hypersensitivity to yeast or HPV vaccine components~* Known autoimmune disorders~* Receipt of immunoglobulins or blood product within 90 days of enrollment (may defer until 90 days completed)~* Serious Adverse Reaction to HPV vaccine

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- 12 months (Type: EXPERIMENTAL): Administration of 3rd dose at 12 months quadrivalent human papillomavirus vaccine
- 6 month (Type: ACTIVE_COMPARATOR): Administration of 3rd dose at 6 months quadrivalent human papillomavirus vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical 1) Patients with angina and documented ischemia or patients with documented silent ischemia 2) Patients who are eligible for intracoronary stenting 3) Age \>18 years, \<75 ages~2. Angiographic 1) De novo lesion 2) Percent diameter stenosis ≥50% 3) Reference vessel size \>2.5 mm by visual estimation 4) Lesion length \>25 mm by visual estimation that is required for long Endeavor stent implantation (planned total stent length \>30mm)~Exclusion Criteria:~1. History of bleeding diathesis or coagulopathy~2. Pregnant~3. Known hypersensitivity or contra-indication to contrast agent, heparin, sirolimus and paclitaxel~4. Limited life-expectancy (less than 1 year) due to combined serious disease~5. ST-elevation acute myocardial infarction~6. Characteristics of lesion 1) Left main disease 2) In-stent restenosis 3) Graft vessels~7. Hematological disease (Neutropenia \<3000/mm3, Thrombocytopenia \<100,000/mm3)~8. Hepatic dysfunction, liver enzyme (ALT and AST) elevation \>3 times normal~9. Renal dysfunction, creatinine \>2.0mg/dL~10. Contraindication to aspirin, clopidogrel or cilostazol~11. planned bifurcation stenting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- cilostazol (Type: EXPERIMENTAL): Cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
- placebo (Type: PLACEBO_COMPARATOR): Control placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12-Week Study of Plecanatide for CIC (The CIC3 Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-80, inclusive~* Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months~* Completed a colonoscopy in accordance with AGA colon cancer screening guidelines (5 years), with no clinically significant findings~* Willing to maintain a stable diet during the study~Exclusion Criteria:~* Loose stool (mushy) or watery (Bristol score 6 or 7) stool in the absence of any laxative or prohibited medicine for \> 25% of BMs during the 3 months prior to screening visit OR during the 14 day pre-treatment assessment~* Active peptic ulcer disease, diabetes or hypertension not adequately treated or not stable~* History of cathartic colon, laxative, enema abuse, or ischemic colitis~* Fecal impaction within 3 months of screening~* Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain~* Unexplained and clinically significant alarm symptoms including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis~* Major surgery, stroke or MI within 60 days of screening~* Participated in a previous plecanatide clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Plecanatide 3.0 mg (Type: ACTIVE_COMPARATOR): Plecanatide tablets 3.0 mg QD for 12 weeks
- Plecanatide 6.0 mg (Type: ACTIVE_COMPARATOR): Plecanatide tablets 6.0 mg QD for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets QD for 12 weeks
- Bisacodyl (Type: OTHER): Rescue medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. male or female subjects (aged 18 or older);~2. provide written informed consent and sign/date a health information release;~3. women of childbearing potential must be willing to practice effective contraception for the duration of the study.~Exclusion Criteria:~1. any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results;~2. use of systemic steroids within 1 month prior to Baseline Visit (Visit 1) or anticipated use at any time during the study (inhaled and intranasal steroids are allowed);~3. sitting systolic blood pressure equal to or greater than 160 mmHg or diastolic blood pressure equal to or greater than 100 mmHg at the Baseline Visit (Visit 1);~4. use of warfarin, heparin, enoxaparin or similar anticoagulants within 2 weeks prior to Baseline Visit (Visit 1) or anticipated use at any time during the study;~5. known allergy or hypersensitivity to the study medications or their components;~6. previous enrollment in an Ozurdex® clinical trial or previous use of an Ozurdex® implant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: SHAM_COMPARATOR): Active bevacizumab (Avastin®) and Sham Ozurdex®
- Group 2 (Type: ACTIVE_COMPARATOR): Active bevacizumab (Avastin®) and Active Ozurdex®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who underwent surgery at William Beaumont Hospital in Royal Oak, Michigan between January 1, 2003, and January 1, 2009.~* Point of care testing identified a blood sugar value less than 69 mg/dl at any time in the perioperative area; or a value between 70-89 mg/dl in the preoperative area; or a glucose value greater than 250 mg/dl in the preoperative area.~Exclusion Criteria:~* Obstetric patients.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes mellitus~* HbA1c 7.0-9.0% (53-75 mmol/mol) (both inclusive)~* Subjects on stable daily dose of sulphonylurea (above or equal to half of the max approved dose according to local label) with or without metformin (above or equal to 1500 mg or max tolerated dose) for at least 90 days prior to screening visit (Visit 1)~* Body Mass Index (BMI) below or equal to 40 kg/m\^2~Exclusion Criteria:~* Any use of oral anti-diabetic drugs (OADs) (other than SU in monotherapy or in combinationwith metformin) below or equal to 90 days prior to screening visit (Visit 1)~* Use of any drug (other than SU in monotherapy or in combination with metformin), which in the Investigators opinion could interfere with the blood glucose level (e.g. systemic corticosteroids)~* Previous treatment with glucagon-like peptide-1 (GLP-1) receptor agonist (e.g. exenatide, liraglutide)~* Treatment with any insulin regimen (short term treatment due to intercurrent illness including gestational diabetes is allowed at the discretion of the Investigator)~* Screening calcitonin above or equal to 50 ng/l~* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)~* Cardiovascular disorders defined as: congestive heart failure (New York Heart Association (NYHA) class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the past 52 weeks prior to screening visit (Visit 1) and/or planned coronary,carotid or peripheral artery revascularisation procedures~* Proliferative retinopathy requiring acute treatment or maculopathy (macular oedema) according to the Investigator's opinion~* Subjects with a clinical significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, endocrinological (except for the Type 2 Diabetes Mellitus),neurological, genitourinary or haematological system that in the opinion of the Investigator,may confound the results of the trial or pose additional risk in administering trial product~* History of chronic pancreatitis or idiopathic acute pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec/liraglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depression~* Diagnosis of a substance use disorder~* Enrolled in clinical care at Creative Alternatives or People Encouraging People for at least 3 months~Exclusion Criteria:~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive screening, testing, immunization, and risk reduction. Screening and testing will take place at study entry, immunization will occur at entry and after 3 and 6 months, and risk reduction will take place at study entry and after 3 and 6 months.
- 2 (Type: PLACEBO_COMPARATOR): Participants will receive enhanced treatment as usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced kidney cancer~Exclusion Criteria:~* Previous treatment for kidney cancer, except surgical removal of kidney tumor

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SUNITINIB MALATE. (Type: EXPERIMENTAL): Sunitinib malate starting dose 37.5 mg daily continuous daily schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete